Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

212 trials

NCT07634016
Recruiting
Global Healthcare Study on Psoriasis
Not applicable · Switzerland · 1 site
Registry update: 28 Sept 2026
NCT05644782
Recruiting
Dietary Approach to Mild-to-moderate Psoriasis
Not applicable · Italy · 3 sites
Registry update: 12 Jan 2026
NCT06912165
Recruiting
A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
Phase 2 · China · 1 site
Registry update: 11 Apr 2025
NCT06398106
Recruiting
Proactive TDM Versus Standard Use of Biologics in Psoriasis
Phase 4 · Belgium · 14 sites
Registry update: 4 Mar 2026
2024-514759-13-01
Recruiting
[18F]Fluoride PET-CT in psoriasis patients at risk for developing psoriatic arthritis
Phase 2 · Netherlands · 1 site
Registry update: 16 Dec 2024
NCT06533423
Recruiting
Effect of a Self-Management Intervention for Patients Newly Diagnosed With Inflammatory Arthritis: The NISMA Trial
Not applicable · Denmark · 2 sites
Registry update: 9 Feb 2026
NCT06454188
Recruiting
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Phase 4 · Belgium, Canada, Poland, United States · 19 sites
Registry update: 3 Apr 2026
NCT06696027
Recruiting
AYLo - AutoimmunitY and Loss of y
Not applicable · Germany · 1 site
Registry update: 10 Apr 2025
NCT06663332
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Phase 3 · Argentina, Australia, Belgium, Brazil, China, Germany, Spain, France, United Kingdom, Israel, Italy, Japan, South Korea, Norway, Poland, Portugal, United States · 58 sites
Registry update: 3 Nov 2026
2024-516919-25-00
Recruiting
Study of the efficacy and safety of etanercept treatment in patients with SAPHO syndrome
Phase 2/3 · Poland · 3 sites
Registry update: 20 Apr 2026
NCT06792487
Recruiting
Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)
Not applicable · Italy · 1 site
Registry update: 24 Jan 2025
NCT06258668
Recruiting
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Not applicable · South Korea · 2 sites
Registry update: 6 Nov 2024
NCT06224634
Recruiting
The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance
Not applicable · Denmark · 1 site
Registry update: 18 Mar 2025
NCT07532486
Recruiting
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis
Not applicable · China · 1 site
Registry update: 16 Apr 2026
NCT06100744
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Phase 3 · Australia, Canada, Germany, Spain, France, United Kingdom, Italy, Poland, United States · 34 sites
Registry update: 1 Sept 2026
NCT06726213
Recruiting
Walk and Talk: Connecting People With Psoriasis
Not applicable · United Kingdom · 1 site
Registry update: 10 Dec 2024
NCT06974474
Recruiting
Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.
Phase 4 · Italy · 1 site
Registry update: 16 May 2025
NCT05815797
Recruiting
Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis
Phase 2 · Hong Kong · 1 site
Registry update: 30 Jul 2026
NCT06387654
Recruiting
Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
Not applicable · France · 1 site
Registry update: 17 Mar 2026
NCT06376474
Recruiting
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
Phase 1 · China · 1 site
Registry update: 4 Dec 2025

Ordered by registry start date. Freshness and sponsorship never change the order.